Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 20/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 18/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7094546 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7091429 | 0.96 | ADRB3 (0.93) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7094866 | 0.94 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7092277 | 0.92 | ADRB3 (0.84) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7095708 | 0.92 | ADRB3 (0.84) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7091452 | 0.91 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7091566 | 0.91 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7095765 | 0.90 | ADRB3 (0.82) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7601016 | 0.90 | ADRB3 (0.82) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7092212 | 0.90 | ADRB3 (0.82) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB3 3/4885ADRB1 2/4885ADRB2 1/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885ADRB1 1/4885ADRB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.